Literature DB >> 3241124

Low density lipoprotein receptor degradation is influenced by a mediator protein(s) with a rapid turnover rate, but is unaffected by receptor up- or down-regulation.

L A Casciola1, D R van der Westhuyzen, W Gevers, G A Coetzee.   

Abstract

Treatment of cultured human skin fibroblasts with cycloheximide retarded the down-regulation of low density lipoprotein (LDL) receptor activity caused by 25-hydroxycholesterol. The rate of LDL receptor degradation, measured directly by means of [35S]methionine pulse-chase experiments, was also markedly inhibited by cycloheximide (or puromycin), suggesting that continuous synthesis of a short-lived mediator protein(s) was necessary for normal LDL receptor turnover. In the absence of cycloheximide, both the up- and down-regulation of LDL receptor activity took place with a half-time of approximately 12 hr. Pulse-chase measurements with [35S]methionine yielded a receptor half-life (t1/2) of 11.7 +/- 2.2 hr (n = 10) in up-regulated cells; the t1/2 in the partially down-regulated state was similar. The presence of LDL or 25-hydroxycholesterol did not alter this degradation rate. Regulation of LDL receptor activity under these various culture conditions therefore probably occurred solely as a result of changes in the rate of receptor synthesis. The cycloheximide-sensitive factor(s) that influences receptor turnover apparently did not play a regulatory role in the up- or down-regulation of the LDL receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3241124

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

1.  Low-density-lipoprotein receptors in human fibroblasts are not degraded in lysosomes.

Authors:  L A Casciola; K I Grant; W Gevers; G A Coetzee; D R van der Westhuyzen
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

2.  Agents which increase cyclic AMP have diverse effects on low-density-lipoprotein-receptor function in human vascular smooth-muscle cells and skin fibroblasts.

Authors:  A Middleton; B Middleton
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

3.  U18666A inhibits intracellular cholesterol transport and neurotransmitter release in human neuroblastoma cells.

Authors:  S M Sparrow; J M Carter; N D Ridgway; H W Cook; D M Byers
Journal:  Neurochem Res       Date:  1999-01       Impact factor: 3.996

4.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

5.  Deletion of two growth-factor repeats from the low-density-lipoprotein receptor accelerates its degradation.

Authors:  D R van der Westhuyzen; M L Stein; H E Henderson; A D Marais; A M Fourie; G A Coetzee
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

6.  Cyclic AMP stimulates the synthesis and function of the low-density lipoprotein receptor in human vascular smooth-muscle cells and fibroblasts.

Authors:  B Middleton; A Middleton
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.